N-terminal modification is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-02-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
Tesamorelin binds the growth hormone–releasing hormone receptor on pituitary somatotroph cells. The receptor signals through the Gs protein, raising intracellular cAMP and activating protein kinase A. That cascade triggers release of stored growth hormone in pulses rather than a steady stream. Because the drug acts at the receptor that normally controls this process, its effect depends on the body's own signaling architecture rather than on a synthetic pathway. The resulting hormone profile reflects the timing of each pulse, not only its size.
Measured responses usually involve growth hormone and insulin-like growth factor 1, known as IGF-1. Growth hormone rises in bursts and is difficult to sample reliably, while IGF-1 shifts more slowly and can be assessed from a single blood draw. Studies therefore treat IGF-1 as the more practical pharmacodynamic marker. Both are indirect, showing that the receptor was engaged rather than that the peptide reached a particular concentration. Direct exposure measurement requires an assay aimed at the molecule itself.
Published work tends to frame tesamorelin as a tool for studying the GHRH axis and as a compound with measurable effects on body composition. Reports often describe visceral adipose tissue as an endpoint, assessed by imaging rather than by inference. Analytical sections commonly describe liquid chromatography with tandem mass spectrometry to confirm identity and purity, because immunoassays may cross-react with related fragments. Where results diverge between studies, differences in assay choice, sampling timing, and population are frequent explanations offered. Whether effects persist after treatment stops remains an open question.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C221H366N72O67S | Reflects a 44-residue peptide with one N-terminal modification |
| Approximate molecular weight | 5136 Da | Sequence length and single acyl group determine the mass |
| Appearance | White to off-white lyophilized powder | Typical form of a purified synthetic peptide |
| Solubility class | Soluble in water and aqueous buffer | Peptide backbone favors aqueous dissolution |
| Common synonyms | GHRH(1-44) analogue; Egrifta | Descriptive name and approved brand name |
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
== Documentation == The documentation of activities by pharmaceutical manufacturers is a license-to-operate endeavor, supporting both the quality of the product produced and satisfaction of regulators who oversee manufacturing operations and determine whether a manufacturing process may continue or must be terminated and remediated.
== Biosynthesis == Lariocidin is a 18 amino acid-long peptide with the sequence SKKSKPGDGKFGRGVKRG, whose N-terminal serine forms an isopeptide bond with the side chain of aspartate 8 and the C-terminal tail is threaded through the loop formed. Lariocidin belongs to the lasso peptide family of the ribosomally synthesized and post-translationally modified peptide (RiPP) class of natural products. Lariocidin biosynthetic gene cluster (BGC) in the genome of the producer encodes a precursor peptide (LrcA), the enzymes required for its modification (LrcB1B2C), export pumps (LrcD1D2), and a self-resistance acetyltransferase LrcE. The biosynthetic machinery installs a characteristic isopeptide bond that creates the macrocycle and generates the threaded, “lasso” topology. In the same BGC researchers identified a peptidase LrcF, whose activity is required for the formation of the LAR-B variant - an internally cyclized derivative of LAR. Heterologous expression of the lariocidin BGC in model host and targeted gene deletion supported the proposed functions of the encoded proteins.
== Causes == The vast majority of trigger digits are idiopathic, meaning there is no known cause. A study of 95,437 people in a diabetes registry in Sweden found that among people with either Type 1 (9,692) or Type 2 (85,755) diabetes, a higher hemoglobin A1C level was modestly associated with diagnosis of trigger digit. Some speculate that repetitive forceful use of a digit leads to narrowing of the fibrous digital sheath in which it runs, but there is little scientific data to support this theory. The relationship of trigger finger to work activities is debatable and there are arguments for and against a relationship to hand use with no experimental evidence supporting a relationship.
Sources: en.wikipedia.org
== Books == Johann Hari (2002). God Save the Queen?. Icon Books. ISBN 978-1-84046-401-6. Johann Hari (2015). Chasing the Scream: The First and Last Days of the War on Drugs. Bloomsbury. ISBN 978-1-62040-890-2. Johann Hari (2018). Lost Connections: Uncovering the Real Causes of Depression – and the Unexpected Solutions. Bloomsbury. ISBN 978-1-63286-830-5. Johann Hari (2021). Stolen Focus: Why You Can't Pay Attention. Bloomsbury. ISBN 978-1-5266-2022-4. Johann Hari (2024). Magic Pill: The Extraordinary Benefits and Disturbing Risks of the New Weight Loss Drugs. Bloomsbury. ISBN 978-1-52667015 {{isbn}}: Check isbn value: length (help).
Copper in the cells is cofactor in cuproenzymes such as cytochrome c oxidase, superoxide dismutase, tyrosinase, dopamine β-hydroxylase, and lysyl oxidase, therefore it supports mitochondrial energy production, antioxidant defense, connective tissue maturation, pigment formation, and neurotransmitter biosynthesis.
=== 2010 census === As of the census of 2010, there were 15,792 people, 6,433 households, and 4,049 families living in the city. The population density was 1,014.9 inhabitants per square mile (391.9/km2). There were 7,057 housing units at an average density of 453.5 per square mile (175.1/km2). The racial makeup of the city was 96.1% White, 0.5% African American, 0.2% Native American, 0.6% Asian, 1.1% from other races, and 1.5% from two or more races. Hispanic or Latino of any race were 3.1% of the population. There were 6,433 households, of which 32.6% had children under the age of 18 living with them, 46.0% were married couples living together, 11.8% had a female householder with no husband present, 5.2% had a male householder with no wife present, and 37.1% were non-families. 30.9% of all households were made up of individuals, and 11.8% had someone living alone who was 65 years of age or older. The average household size was 2.38 and the average family size was 2.97. The median age in the city was 37.5 years. 24.5% of residents were under the age of 18; 8.5% were between the ages of 18 and 24; 26.8% were from 25 to 44; 25.6% were from 45 to 64; and 14.7% were 65 years of age or older. The gender makeup of the city was 48.0% male and 52.0% female.
Sources: en.wikipedia.org
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.
It binds the growth hormone-releasing hormone receptor on anterior pituitary cells. Activation of that receptor promotes synthesis and release of growth hormone. The effect propagates through the growth hormone and insulin-like growth factor 1 axis.
Native GHRH is cleared quickly by peptidases, which limits how long it can stimulate its receptor. The added group hinders one of the primary cleavage enzymes. The practical consequence is a longer period of receptor activity per dose.
It acts on the growth hormone–releasing hormone receptor, a Gs-coupled receptor found on pituitary somatotroph cells. Activation raises cAMP and prompts pulsatile hormone release.